This simulated analysis of cost-sharing in member nations of the Organisation for Economic Co-operation and Development found a large variation in costs borne by patients, often dependent on age, comorbidities, and socioeconomic status.
This population-based cohort study evaluates trends in the prescription and cost of generic atorvastatin among patients with commercial insurance coverage.
The Viewpoint discusses the effects of “patent trolls” on generic drug prices and availability.
This survey study investigates attitudes toward prescribing generic drugs among internists and specialists in endocrinology, hematology, and infectious diseases.
This cross-sectional study estimates potential savings through therapeutic substitution in terms of both overall and out-of-pocket expenditures of branded drugs when a generic in the same class with the same indication was available.
This study examines prescription data from the University of Pennsylvania Health System outpatient clinics to compare generic medication prescription rates before and after a redesign of the electronic health record display defaults.
This study uses Medicare Part D prescriptions claims data and Massachusetts physicians payment database data to evaluate associations between industry payments to physicians and prescribing of brand-name statins.
This study found that between 1991 and 2014, there was an upward trend in Medicaid payments for insulin products regardless of formulation, duration of action, and whether the product was patented, which suggests a lack of price competition for this class of medications.